

Philipp Ivanyi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3766192/philipp-ivanyi-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167
papers

2,466
citations

26
h-index

42
g-index

197
ext. papers

2,706
ext. citations

3.8
avg, IF

4.34
L-index

#	Paper	IF	Citations
167	Genetic studies on male sterility of hybrids between laboratory and wild mice (<i>Mus musculus</i> L.). <i>Genetical Research</i> , 1974 , 24, 189-206	1.1	165
166	An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. <i>Human Immunology</i> , 1986 , 16, 169-81	2.3	159
165	Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules. <i>Annals of the Rheumatic Diseases</i> , 1987 , 46, 353-6	2.4	91
164	HLA-restricted recognition of viral antigens in HLA transgenic mice. <i>Nature</i> , 1987 , 329, 447-9	50.4	83
163	Subtypes of HLA-B27 detected by cytotoxic T lymphocytes and their role in self-recognition. <i>Human Immunology</i> , 1982 , 5, 259-68	2.3	83
162	Genetic association between H-2 gene and testosterone metabolism in mice. <i>Nature: New Biology</i> , 1972 , 238, 280-1		70
161	Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. <i>American Journal of Transplantation</i> , 2013 , 13, 911-918	8.7	66
160	Germ-free mice do not develop ankylosing enthesopathy, a spontaneous joint disease. <i>Human Immunology</i> , 2000 , 61, 555-8	2.3	66
159	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	57
158	Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. <i>BMC Cancer</i> , 2010 , 10, 695	4.8	56
157	Biochemical analysis of variant HLA-B27 antigens. <i>Human Immunology</i> , 1983 , 6, 111-7	2.3	49
156	TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). <i>Annals of Oncology</i> , 2015 , 26, 561-7	10.3	46
155	Identification of new B27 subtypes (B27C and B27D) prevalent in oriental populations. <i>Human Immunology</i> , 1986 , 16, 163-8	2.3	45
154	Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity. <i>Experimental Hematology</i> , 2011 , 39, 1152-60	3.1	41
153	In vitro-isolated human cytotoxic T-lymphocyte clones detect variations in serologically defined HLA antigens. <i>Immunogenetics</i> , 1982 , 16, 503-12	3.2	40
152	Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 617-20	11.5	34
151	Evidence for a regulatory role of the T8 (CD8) antigen in antigen-specific and anti-T3-(CD3)-induced lytic activity of allospecific cytotoxic T lymphocyte clones. <i>European Journal of Immunology</i> , 1986 , 16, 1363-71	6.1	34

150	Identification of human CML target. HLA-B locus (B12) antigen variants defined by CTL generated between B locus-identical (B12) responder-stimulator pairs. <i>Journal of Immunology</i> , 1982 , 128, 949-55	5.3	34
149	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019 , 39, 714-726	7.9	28
148	A search for association of HLA antigens with paranoid schizophrenia. A9 appears as a possible marker. <i>Tissue Antigens</i> , 1983 , 22, 186-93		28
147	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016 , 33, 80	3.7	27
146	HL-A antigens in aged persons. <i>Tissue Antigens</i> , 1975 , 6, 269-71		27
145	Induction of H-2-specific antibodies by injections of syngeneic Sendai virus-coated cells. <i>European Journal of Immunology</i> , 1987 , 17, 27-35	6.1	27
144	Relations of HL-A and Rh Systems to Immune Reactivity. <i>Vox Sanguinis</i> , 1974 , 26, 470-482	3.1	27
143	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , 2018 , 93, 150-153	7.5	26
142	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3555-3564	2.2	26
141	Anti-H-2 antibodies induced by syngeneic immunization. <i>Immunogenetics</i> , 1980 , 10, 319-32	3.2	25
140	Absence of autoantibodies to peptides shared by HLA-B27.5 and <i>Klebsiella pneumoniae</i> nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome. <i>Annals of the Rheumatic Diseases</i> , 1992 , 51, 783-9	2.4	24
139	Sex-dependent and H-2-linked influence on expressivity of the brachyury gene in mice. <i>Journal of Heredity</i> , 1974 , 65, 369-72	2.4	23
138	Individual mice of one inbred strain produce anti-H-2 and anti-HLA antibodies of different specificities. <i>Tissue Antigens</i> , 1978 , 12, 32-8		23
137	HLA antigens in schizophrenia. <i>Tissue Antigens</i> , 1976 , 8, 217-20		22
136	A subpopulation of mouse cytotoxic T lymphocytes recognizes allogeneic H-2 class I antigens in the context of other H-2 class I molecules. <i>Journal of Experimental Medicine</i> , 1991 , 174, 15-9	16.6	22
135	Fine specificity of human HLA-B7-specific cytotoxic T-lymphocyte clones. I. Identification of HLA-B7 subtypes and histotopes of the HLA-B7 cross-reacting group. <i>Human Immunology</i> , 1986 , 16, 375-89	2.3	22
134	Natural H-2-specific antibodies in sera of aged mice. <i>Immunogenetics</i> , 1982 , 15, 95-102	3.2	22
133	Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application. <i>PLoS ONE</i> , 2012 , 7, e51644	3.7	21

132	Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. <i>European Journal of Haematology</i> , 2005 , 75, 68-72	3.8	21
131	HLA antigens as possible markers of heterogeneity in schizophrenia. <i>International Journal of Immunogenetics</i> , 1978 , 5, 165-72		20
130	Histocompatibility gene organization and mixed lymphocyte reaction. <i>Nature: New Biology</i> , 1971 , 230, 271-2		20
129	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016 , 33, 59	3.7	20
128	Histopathology of murine ankylosing enthesopathy. <i>Pathology Research and Practice</i> , 1998 , 194, 797-803,4		19
127	Specificity of anti-HLA-B27 cytotoxic T lymphocytes. <i>Tissue Antigens</i> , 1983 , 22, 267-82		19
126	A cloned cytotoxic T-lymphocyte (CTL) line recognizing a subtype of HLA B27. <i>Human Immunology</i> , 1984 , 9, 231-42	2.3	19
125	Blind confirmation of Geczy factor in ankylosing spondylitis. <i>Lancet, The</i> , 1985 , 2, 943-4	40	18
124	Blind confirmation in Leiden of Geczy factor on the cells of Dutch patients with ankylosing spondylitis. <i>Human Immunology</i> , 1986 , 17, 239-45	2.3	18
123	Allo-Antigens and Antigenic Factors of Human Leukocytes. <i>Vox Sanguinis</i> , 1966 , 11, 326-331	3.1	18
122	Cross-reactivity among the products of three nonallelic H-2 loci, H-2Ld, H-2Dq, and H-2Kk. <i>Transplantation</i> , 1979 , 28, 339-42	1.8	17
121	Grouped caging predisposes male mice to ankylosing enthesopathy. <i>Annals of the Rheumatic Diseases</i> , 1996 , 55, 645-7	2.4	16
120	Frequency analysis of HLA-specific cytotoxic T lymphocyte precursors in humans. <i>Transplantation</i> , 1991 , 51, 1096-103	1.8	16
119	Bevacizumab-associated glomerular microangiopathy. <i>Modern Pathology</i> , 2019 , 32, 684-700	9.8	16
118	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2010 , 28, 391-8	4	15
117	HLA expression and function in single and double HLA-B27-transgenic mice. <i>Tissue Antigens</i> , 1989 , 34, 50-63		15
116	Conventional alloantisera can recognize the same HLA-B27 polymorphism as detected by cytotoxic T lymphocytes. <i>Human Immunology</i> , 1987 , 20, 265-71	2.3	15
115	Lymphocytotoxic antibodies produced by H-2 allo-immunisation distinguish between MuLV-positive and -negative substrains of the same H-2 haplotype. <i>Nature</i> , 1979 , 282, 843-5	50.4	15

114	Prognostic impact of PD-1 and its ligands in renal cell carcinoma. <i>Medical Oncology</i> , 2017 , 34, 99	3.7	14
113	HLA-Cw4 in paranoid schizophrenia. <i>Tissue Antigens</i> , 1977 , 9, 41-4		14
112	Identification of novel regulators in T-cell differentiation of aplastic anemia patients. <i>BMC Genomics</i> , 2006 , 7, 263	4.5	14
111	Cytotoxic effect of anti-H-2 and anti-Ia antisera on human B and T cells. <i>Scandinavian Journal of Immunology</i> , 1977 , 6, 431-7	3.4	14
110	The major histocompatibility antigens in various species. <i>Current Topics in Microbiology and Immunology</i> , 1970 , 53, 1-90	3.3	14
109	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. <i>Medical Oncology</i> , 2016 , 33, 120	3.7	14
108	Self-restricted primary human histocompatibility leukocyte antigen (HLA)-specific cytotoxic T lymphocytes. <i>International Immunology</i> , 1993 , 5, 103-7	4.9	13
107	Dysfunction of HLA-B27. <i>Scandinavian Journal of Rheumatology</i> , 1990 , 87, 51-69; discussion 69	1.9	13
106	Variations in the T-cell repertoire against HLA antigens in humans. <i>Human Immunology</i> , 1990 , 27, 1-15	2.3	13
105	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017 , 34, 71	3.7	12
104	Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice. <i>Annals of the Rheumatic Diseases</i> , 1995 , 54, 754-6	2.4	12
103	Polymorphic and autoreactive H-2-specific monoclonal antibody isolated after injections of syngeneic Sendai virus-coated lymphocytes. <i>Immunogenetics</i> , 1986 , 24, 402-8	3.2	12
102	Activation of cytotoxic T lymphocytes in HLA-A, -B and -C-identical responder-stimulator pairs. II. New subtypes of HLA-Bw35. <i>Tissue Antigens</i> , 1984 , 24, 90-7		12
101	Anti-MHC immunity detected prior to intentional alloimmunization. III. Natural autoreactive H-2-specific antibodies. <i>Immunogenetics</i> , 1985 , 21, 491-504	3.2	12
100	Individual mice recognize the complex nature of H-2 antigens; unexpected reactions (anti-Kk) in anti-BALB/c-H-2d sera produced in the BALB/c-H-2db mutant. <i>Transplantation Proceedings</i> , 1979 , 11, 642-6	1.1	12
99	Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. <i>Deutsches Arzteblatt International</i> , 2008 , 105, 232-7	2.5	12
98	Allo-Antigens and Antigenic Factors of Human Leukocytes: A Hypothesis. <i>Vox Sanguinis</i> , 2009 , 11, 326-331		11
97	Different linkage disequilibria of HLA-B27 subtypes and HLA-C locus alleles. <i>Tissue Antigens</i> , 1988 , 32, 74-7		11

96	Testosterone and testosterone binding in murine plasma. <i>Steroidologia</i> , 1971 , 2, 113-20		11
95	Molecular targeted therapies for solid tumors: management of side effects. <i>Oncology Research and Treatment</i> , 2009 , 32, 129-38	2.8	10
94	Immunogenetics of the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 1993 , 5, 436-45	5.3	10
93	Specificity and frequency of primary anti-HLA cytotoxic T lymphocytes in normal and HLA-B27.2-, HLA-B27.5-, and HLA-Cw3-transgenic mice. A transgenic model for MHC xenoantigen recognition. <i>Journal of Immunology</i> , 1990 , 144, 4513-9	5.3	10
92	Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. <i>World Journal of Urology</i> , 2011 , 29, 355-60	4	9
91	Strong association of HLA-B27 heavy chain with beta 2-microglobulin. <i>Human Immunology</i> , 2000 , 61, 1197-201	2.3	9
90	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020 , 16, 2307-2328	3.6	9
89	Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres. <i>Medical Oncology</i> , 2014 , 31, 147	3.7	8
88	Reconstitution and phenotype of Tregs in CMV reactivating patients following allogeneic hematopoietic stem cell transplantation. <i>Immunological Investigations</i> , 2013 , 42, 18-35	2.9	8
87	Anti-MHC immunity detected prior to intentional alloimmunization. IV. Natural monoclonal H-2-specific antibodies. <i>International Journal of Immunogenetics</i> , 1986 , 13, 287-97		7
86	Activation of cytotoxic T lymphocytes in HLA-A, -B and -C-identical responder-stimulator pairs. I. Variations in generation of anti-class-II CTL in primary mixed lymphocyte cultures. <i>Tissue Antigens</i> , 1984 , 24, 81-9		7
85	Allo-antigens and antigenic factors of human leukocytes. A hypothesis. <i>Vox Sanguinis</i> , 1966 , 11, 326-31	3.1	7
84	Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. <i>Scientific Reports</i> , 2019 , 9, 1741	4.9	6
83	Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	6
82	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 280-290.e3	3.3	6
81	Individual differences in the cytotoxic T-lymphocyte response in man to public HLA determinants. <i>Cellular Immunology</i> , 1986 , 103, 252-71	4.4	6
80	Fine specificity of cytotoxic T lymphocytes directed against H-2Ld. <i>Immunogenetics</i> , 1981 , 12, 75-88	3.2	6
79	Human Ia molecules carrying DC1 or BR4X7 determinants are not homologous to murine I-E molecules. <i>Immunogenetics</i> , 1982 , 16, 187-99	3.2	6

78	Natural autoreactive H-2-specific serum antibodies in a group of BALB/cBy (H-2d) mice. <i>Tissue Antigens</i> , 1986 , 27, 106-11		5
77	Sexual dimorphism, but not testosterone itself, is responsible for ankylosing enthesitis of the ankle in B10.BR (H-2k) male mice. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 130-2	2.4	5
76	Solitary caging protects mice from ankylosing enthesopathy. <i>Clinical Rheumatology</i> , 1996 , 15 Suppl 1, 32-3	3.9	5
75	Unexpected lympho-cytotoxic reactions of anti-H-2 sera on normal lymph-node cells: are they due to altered H-2 structures or anti-viral antibodies?. <i>International Journal of Immunogenetics</i> , 1980 , 7, 91-7		5
74	A syngeneic anti tumor serum recognizing a complex H-2 alloantigen. <i>Immunobiology</i> , 1979 , 156, 110-20	3.4	5
73	H-2 influence on ankylosing enthesopathy of the ankle (ANKENT). <i>Folia Biologica</i> , 1992 , 38, 258-62	0.7	5
72	Antigen Report: HLA-B27 1984 , 144-144		5
71	c-Met in chromophobe renal cell carcinoma. <i>Medical Oncology</i> , 2017 , 34, 15	3.7	4
70	Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy-Real-World Clinical Impressions and Comparative Review of the Literature. <i>Frontiers in Oncology</i> , 2020 , 10, 808	5.3	4
69	Self-expanding metallic stent placement with laryngeal mask in lung transplant recipients. <i>Transplantation Proceedings</i> , 2010 , 42, 4595-9	1.1	4
68	Frequency of naturally occurring H-2-specific antibodies in mouse sera monitored by "superreactive" rabbit complement. <i>Tissue Antigens</i> , 1985 , 26, 259-61		4
67	Comparison of amino acid compositions of peptides eluted from HLA-B27 molecules of healthy individuals and patients with ankylosing spondylitis. <i>Immunology Letters</i> , 2006 , 103, 135-41	4.1	4
66	Immunization with syngeneic Sendai virus-infected cells induce no MHC-restricted antibodies but antibodies specific for H-2 class I determinants. <i>Immunogenetics</i> , 1989 , 29, 108-11	3.2	4
65	HL-A ANTIGENS IN JUVENILE RHEUMATOID ARTHRITIS. <i>International Journal of Immunogenetics</i> , 1976 , 3, 229-236		4
64	Anti-H-2Dd antibodies cross-react with HLA-A11 and Aw31. <i>Tissue Antigens</i> , 1978 , 11, 439-42		4
63	Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. <i>Journal of Kidney Cancer and VHL</i> , 2017 , 4, 8-15	1.4	4
62	B27 Subtypes 1984 , 418-419		4
61	Temsirolimus Is Active in Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Failing Platinum-Based Chemotherapy and Cetuximab: Efficacy and Toxicity Data from the Phase II Temhead Study. <i>Annals of Oncology</i> , 2012 , 23, ix336-ix337	10.3	4

60	Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?. <i>World Journal of Urology</i> , 2016 , 34, 909-15	4	4
59	PROLONGED SURVIVAL OF MATERNAL SKIN GRAFTS IN NEWBORN RABBITS. <i>Annals of the New York Academy of Sciences</i> , 2006 , 129, 234-240	6.5	3
58	Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. <i>Experimental Hematology</i> , 2005 , 33, 804-10	3.1	3
57	Naturally occurring cytotoxic human antibodies recognize H-2-controlled murine lymphocyte antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1983 , 80, 4479-83 ¹¹⁵	11.5	3
56	Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?. <i>Clinical and Experimental Metastasis</i> , 2021 , 38, 257-261	4.7	3
55	Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 53-59.e1	3.3	3
54	CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. <i>Acta Radiologica Open</i> , 2017 , 6, 2058460117694216	1.2	2
53	Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant center. <i>Future Oncology</i> , 2019 , 15, 3739-3750	3.6	2
52	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11536-11536	2.2	2
51	A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 678-678	2.2	2
50	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. <i>Molecular and Clinical Oncology</i> , 2020 , 13, 72	1.6	2
49	A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5103-TPS5103	2.2	2
48	Cross-reactions of Class II Histocompatibility Antigens of Various Species 1986 , 128-153		2
47	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 3075-3078	4.9	2
46	Impact of sarcopenia in advanced and metastatic soft tissue sarcoma. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 2151-2160	4.2	2
45	Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature. <i>Oncology Research and Treatment</i> , 2019 , 42, 382-386	2.8	1
44	Systemtherapie des Nierenzellkarzinoms. <i>Onkologe</i> , 2019 , 25, 517-522	0.1	1
43	High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy?. <i>Annals of Hematology</i> , 2014 , 93, 1053-5	3	1

42	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. <i>World Journal of Urology</i> , 2010 , 28, 311-7	4	1
41	Constancy of cross-reactivity patterns in sera of individual mice during the anti-H-2 response. <i>Tissue Antigens</i> , 1980 , 16, 49-55		1
40	Allo-immune anti-Iak sera of individual mice detect HLA-DR-associated polymorphism on human B cells. <i>Tissue Antigens</i> , 1983 , 22, 134-41		1
39	Estimates of cytotoxic T-lymphocyte precursor frequencies against HLA class I antigens in responder-stimulator pairs with a negative mixed lymphocyte culture reaction. <i>Human Immunology</i> , 1995 , 44, 97-102	2.3	1
38	Prognostic significance of free testosterone levels during chemotherapy with carboplatin plus docetaxel (CD) in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5029-5029	2.2	1
37	Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16070-e16070	2.2	1
36	Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. <i>Cellular Oncology</i> , 2010 , 32, 101-8		1
35	A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS11075-TPS11075	2.2	1
34	Heterogeneity of HLA-B7 as Detected by Cytotoxic T Cell Clones 1984 , 479-480		1
33	Extracorporeal portosystemic shunt in secondary Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2020 , 73, 974-976	13.4	1
32	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020 , 2020, 8865054	4.5	1
31	Therapie des Nierenzellkarzinoms. <i>Onkologe</i> , 2006 , 12, 1153-1168	0.1	0
30	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021 , 12, 127-134	0.4	0
29	Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.. <i>Journal of Cancer</i> , 2022 , 13, 1706-1712	4.5	0
28	The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. <i>Urologia Internationalis</i> , 1-9	1.9	0
27	Immunonkologische Therapie vs. Chemotherapie - aktuelle Konzepte bei Hals-Kopf-Tumoren. <i>Tumor Diagnostik Und Therapie</i> , 2019 , 40, 98-101	0.1	
26	Revolution in der Systemtherapie des metastasierten Nierenzellkarzinoms. <i>Der Nephrologe</i> , 2020 , 15, 12-19	0.1	
25	c-Met Onkogen bei Nierenzellkarzinomen. <i>Tumor Diagnostik Und Therapie</i> , 2017 , 38, 381-385	0.1	

24	Nierenzellkarzinom. <i>Best Practice Onkologie</i> , 2007 , 2, 4-13	0
23	Regulation of T Cell Homeostasis and Cell Cycling in Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 2767-2767	2.2
22	Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4581-4581	2.2
21	Prognostic value of testosterone levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17069-e17069	2.2
20	Association of multimodality treatment (MT) with improved overall survival (OS) in patients (pts) with advanced/metastatic soft tissue sarcoma (a/m STS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e23566-e23566	2.2
19	Sarcopenia (SMI(+)) in patients (pts) with advanced or metastatic soft tissue sarcoma (a/mSTS): Potential parameter for risk prediction during multimodal therapy (MT)?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11069-11069	2.2
18	Which patients with pre-treated locally advanced or metastatic sarcoma benefit most from trabectedin treatment: First results of a retrospective study of the German Interdisciplinary Sarcoma Group (GISG-14 - ReTraSarc).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11554-11554	2.2
17	Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17103-e17103	2.2
16	Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021 , 1-8	0.6
15	Naturally Occurring H-2 Specific Antibodies 1988 , 7-13	
14	Individual Differences Among Syngeneic Mice in Immune Response to Alloantigens and Modified Self-MHC-Antigens 1989 , 122-133	
13	Confusion of therapeutic approaches. <i>Deutsches A&#x0308;rztblatt International</i> , 2014 , 111, 405	2.5
12	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5084-5084	2.2
11	Prognostic value of free testosterone (FT) levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5039-5039	2.2
10	High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastatic hormone-refractory prostate cancer (HRPC). <i>Journal of Clinical Oncology</i> , 2009 , 27, e16041-e16041	2.2
9	Association of therapy with sunitinib and treatment-related hyperparathyroidism in renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, e16023-e16023	2.2
8	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 172-172	2.2
7	Regulatory T Cells of G-CSF Mobilized Stem Cell Donors Qualify for Clinical Applications,. <i>Blood</i> , 2011 , 118, 4055-4055	2.2

6	Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 420-420	2.2
5	Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 523-523	2.2
4	Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 75-75	2.2
3	Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 144-144	2.2
2	Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 145-145	2.2
1	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. <i>Scientific Reports</i> , 2021 , 11, 16457	4.9